Studies of the pathogenesis, diagnosis and treatment of hemorrhagic diseases are proposed, with emphasis on the following areas: Membrane platelet markers; immunologic and immunochemical studies: Membrane constitutents to which platelet antibodies bind and the mechanism of drug-antibody-platelet interaction in drug-induced immune thrombocytopenia will be characterized at a molecular level. The variable expression of HLA-A and B markers on platelets and its implications for platelet transfusion therapy will be explored. Immune disorders of platelets; immunologic aspects of platelet transfusion therapy: Studies will be conducted to improve the sensitivity and specificity of platelet antibody detection and measurement of platelet associated immunoglobulins. The relationship of previously undescribed, warm-reactive macroglobulin specific for an enzyme-activated site on normal platelets to the pathogenesis of autoimmune thrombocytopenic purpura of childhood will be defined. The natural history and response to therapy of neonatal alloimmune thrombocytopenic purpura and post-transfusion purpura will be further characterized. Studies to improve matching of platelets for alloimmunized thrombocytopenic patients and to define the importance of circulating immune complexes in the response to platelet transfusions will be conducted. Optimum conditions for isolation and short-term preservation of platelets: Methods to improve the quality of platelet concentrates will be sought with emphasis on the use of inhibitors of adenylate cyclase, the significance of activation of the endogenous, calcium-activated protease of platelets, and the mode of agitation during storage. The importance of leukocytes in platelet preservation will be further characterized. Human platelet heterogeneity: physiologic significance: Studies of the factors that determine buoyant density of human platelets, the relationship of buoyant density to platelet age, and the changes that occur in human platelets during the aging process will be conducted.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL013629-17
Application #
3334675
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1979-07-01
Project End
1989-06-30
Budget Start
1986-07-01
Budget End
1987-06-30
Support Year
17
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Bloodcenter of Wisconsin, Inc.
Department
Type
DUNS #
City
Milwaukee
State
WI
Country
United States
Zip Code
53233
Jones, Curtis G; Pechauer, Shannon M; Curtis, Brian R et al. (2018) Normal plasma IgG inhibits HIT antibody-mediated platelet activation: implications for therapeutic plasma exchange. Blood 131:703-706
Curtis, Brian R; Hsu, Yen-Michael S; Podoltsev, Nikolai et al. (2018) Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies. Blood 131:1486-1489
Jones, Curtis G; Pechauer, Shannon M; Curtis, Brian R et al. (2017) A Platelet Factor 4-Dependent Platelet Activation Assay Facilitates Early Detection of Pathogenic Heparin-Induced Thrombocytopenia Antibodies. Chest 152:e77-e80
Padmanabhan, Anand; Jones, Curtis G; Pechauer, Shannon M et al. (2017) IVIg for Treatment of Severe Refractory Heparin-Induced Thrombocytopenia. Chest 152:478-485
Falk, Gavin; Winans, Charles G; Bowens, Krista et al. (2016) An unexpected development after surgery-post-transfusion purpura! Am J Hematol 91:848-51
Bougie, Daniel W; Nayak, Dhirendra; Aster, Richard H (2016) Immune destruction of human platelets in the NOD/scid mouse. Transfusion 56:2648-2649
Fuentes, Rudy E; Zaitsev, Sergei; Ahn, Hyun Sook et al. (2016) A chimeric platelet-targeted urokinase prodrug selectively blocks new thrombus formation. J Clin Invest 126:483-94
Padmanabhan, Anand; Jones, Curtis G; Curtis, Brian R et al. (2016) A Novel PF4-Dependent Platelet Activation Assay Identifies Patients Likely to Have Heparin-Induced Thrombocytopenia/Thrombosis. Chest 150:506-15
Padmanabhan, Anand; Jones, Curtis G; Bougie, Daniel W et al. (2015) A modified PF4-dependent, CD62p expression assay selectively detects serotonin-releasing antibodies in patients suspected of HIT. Thromb Haemost 114:1322-3
Sullivan, Mia J; Peterson, Julie; McFarland, Janice G et al. (2015) A new low-frequency alloantigen (Kha(b) ) located on platelet glycoprotein IIIa as a cause of maternal sensitization leading to neonatal alloimmune thrombocytopenia. Transfusion 55:1584-5

Showing the most recent 10 out of 131 publications